Impact of SF3B1 mutation on outcomes in myelofibrosis.

Authors

null

Prithviraj Bose

The University of Texas MD Anderson Cancer Center, Houston, TX

Prithviraj Bose , Jayastu Senapati , Lucia Masarova , Naveen Pemmaraju , Guillermo Montalban Bravo , Sherry Pierce , Lingsha Zhou , Guillermo Garcia-Manero , Hagop M. Kantarjian , Srdan Verstovsek

Organizations

The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Funding

No funding received

Background: Splicing factor 3B subunit 1 (SF3B1) mutations have been shown to confer a unique phenotype in MDS and MDS/MPN overlap syndromes, with ring sideroblasts, thrombocytosis and favorable prognosis. In myelofibrosis (MF) the frequency of SF3B1 mutation is <10% and may play a less important role in disease outcomes (Lasho et. al, Leukemia, 2011). Methods: We retrospectively analyzed all patients (pts) with WHO-defined MF (primary, including pre-fibrotic MF, or progressed from PV or ET) seen at our center from Jan. 2017 through Jul. 2021. We compared disease phenotypes, MPN driver and co-occurring mutations, cytogenetics, dynamic IPSS (DIPSS) score, transfusion requirements, treatment characteristics and survival outcomes between patients with SF3B1-mutated (SF3B1+) and -wild type (SF3B1-) MF. Results: A total of 381 pts were identified, 29 (8%) of whom were SF3B1+. There were similar frequencies of JAK2, CALR, MPL mutations and “triple negative” MF in the 2 groups (Table). The median number of SF3B1 mutations was 1 (range, 1-2); K666N being the most common (52%). The 2 groups were similar in regard to their baseline hemoglobin, white blood cell counts, platelets, co-occurring mutations, symptom burden and DIPSS but more SF3B1+ pts were PRBC transfusion-dependent at presentation than SF3B1- pts (38% vs. 15%, p=0.003). At a median follow up of 17.2 months for the entire cohort (range, 0.1- 52.2 mos., 22.6 mos. for SF3B1+ and 16.8 mos. for SF3B1-), 41 pts had died [14% SF3B1+ and 10% SF3B1-, p=0.5] and 7 pts (1 SF3B1+ and 6 SF3B1-) had leukemic transformation. The median estimated OS was 230 months for SF3B1- vs. not reached for SF3B1+ pts (p = 0.6). Conclusions:SF3B1 mutation is an uncommon event in MF and does not substantially affect disease phenotype and outcomes. MF pts with SF3B1 mutation are more likely to be PRBC transfusion dependent.

Characteristics
SF3B1+ (N= 29)
SF3B1- (N= 352)
P value
N (%) /Median[range]
Age (yrs.)
72 [54-91]
69 [21-89]

Males
24 (83)
202 (57)

Diagnosis
Primary MF

Post ET MF

Post PV MF
21 (72)

5 (17)

3 (1)
226 (64)

69 (20)

57 (16)

Baseline CBC
Hb (g/dl)

WBC (109/L)

Platelet (109/L)
9.7 [6.9-18.4]

8.3 [1.3-73.3]

230 [19-1188]
10.5 [5.5-17.6]

8.5 [1.1-212.1]

216 [1-1271]
0.4

0.9

0.5
Driver mut.
JAK2CALRMPL

Triple negative

JAK2 allele burden


18 (62)

5 (17)

3 (10)

3 (10)

n=28

45 [1-81] %
214 (60)

82 (23)

29 (8)

32 (9)

n=343

47 [1-99] %
0.9

0.6

0.7

0.7


0.5
Co-mut.
Splicing mutations

(SRSF2, ZSRS2, U2AF1)

Epigenetic mutations

(ASXL1, TET2, IDH1/2, DNMT3A, EZH2)

TP53 mutation
n=20

3 (15)

15 (75)

2 (10)
n=205

59 (29)

157 (76)

10 (5)
0.3

0.9

0.3
CTG
Non diploid karyotype
n=25

12 (48)
n=264

102 (39)
0.4
BM fibrosis
Grade 3
n=29

3 (24)
n=274

113 (41)
0.001
DIPSS
Low

Intermediate 1

Intermediate 2

High
1 (3)

10 (34)

15 (52)

3 (10)
13 (4)

153 (43)

119 (34)

67 (19)
0.3
Transfusion dependency
PRBC

Platelet
11 (38)

0 (0)
52 (15)

4 (1)
0.003

0.99
Treatment
Ruxolitinib

Sotatercept
14 (48)

2 (14)
152 (43)

9 (3)
0.7

0.2
Events
Leukemic transformation

Death
1 (3)

4 (14)
6 (2)

37 (10)
0.4

0.2

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e19080)

DOI

10.1200/JCO.2022.40.16_suppl.e19080

Abstract #

e19080

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

GLS in Philadelphia-negative and JAK2 V617F-driven myeloproliferative neoplasms (MPNs).

First Author: Michele Ciboddo

First Author: Bartlomiej Przychodzen

First Author: Ciro Roberto Rinaldi